← Back to Search

Treatment for Motor Neuron Disease

N/A
Waitlist Available
Led By Shafeeq Ladha, MD
Research Sponsored by Barrow Neurological Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up every 6 months through month 18
Awards & highlights

Summary

This study aims to establish a biorepository and phenotyping database to investigate longitudinal changes in ALS subjects. Blood, including DNA and RNA, cerebrospinal fluid (CSF) and electrophysiologic measures will be collected every 6 months over 1 and a half years. The database and specimen repository will be made available to ALS researchers on a merit basis.

Eligible Conditions
  • Motor Neuron Disease
  • Lou Gehrig's Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~every 6 months through month 18
This trial's timeline: 3 weeks for screening, Varies for treatment, and every 6 months through month 18 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
ALS Functional Rating Scale Revised (ALSFRS-R)
ALS cognitive behavioral screen (ALS-CBS)
Familial benign pemphigus
+4 more
Other outcome measures
MRI Cytography

Find a Location

Who is running the clinical trial?

Barrow Neurological InstituteLead Sponsor
25 Previous Clinical Trials
6,993 Total Patients Enrolled
3 Trials studying Motor Neuron Disease
100 Patients Enrolled for Motor Neuron Disease
ALS AssociationOTHER
44 Previous Clinical Trials
17,133 Total Patients Enrolled
41 Trials studying Motor Neuron Disease
17,028 Patients Enrolled for Motor Neuron Disease
Shafeeq Ladha, MDPrincipal InvestigatorBarrow Neurological Institute
1 Previous Clinical Trials
22 Total Patients Enrolled
1 Trials studying Motor Neuron Disease
22 Patients Enrolled for Motor Neuron Disease
~4 spots leftby Sep 2025